The global market for Co-immunoprecipitation (Co-IP) Service was valued at US$ 477 million in the year 2024 and is projected to reach a revised size of US$ 676 million by 2031, growing at a CAGR of 5.1% during the forecast period.
Co-immunoprecipitation (Co-IP) service is a method for studying protein interactions based on the interaction between antibodies and antigens. The principle is to use endogenous target proteins in cells as bait, co incubate target protein antibodies with total cell proteins, and promote the formation of immune complexes. Subsequently, protein A/G that can bind to the target protein antibody is added to form a "binding protein target protein target protein antibody" complex. After purification, the immune complex is separated by gel electrophoresis, combined with Western blot or mass spectrometry technology, so as to purify the target protein and qualitatively detect antigen or antibody.
North American market for Co-immunoprecipitation (Co-IP) Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Co-immunoprecipitation (Co-IP) Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Co-immunoprecipitation (Co-IP) Service in Drug Development is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Co-immunoprecipitation (Co-IP) Service include Creative Proteomics, Lifeasible, ThermoFisher Scientific, Profacgen, Creative BioMart, Biologics International Corp, Creative Diagnostics, CD BioSciences, Beijing Abace Biology, Nanjing Detai Bioengineering, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Co-immunoprecipitation (Co-IP) Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Co-immunoprecipitation (Co-IP) Service.
The Co-immunoprecipitation (Co-IP) Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Co-immunoprecipitation (Co-IP) Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Co-immunoprecipitation (Co-IP) Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Creative Proteomics
Lifeasible
ThermoFisher Scientific
Profacgen
Creative BioMart
Biologics International Corp
Creative Diagnostics
CD BioSciences
Beijing Abace Biology
Nanjing Detai Bioengineering
Guangzhou Fitgene Biotechnology
Nanjing Zoonbio Biotechnology
Shanghai Beyotime Biotechnology
Beijing Bio-Tech Pack Scientific
Wuhan Genecreate
Wuhan Biorun BioSciences
Segment by Type
Tag Protein Immunoprecipitation
Non Tagged Protein Immunoprecipitation
Chromatin Immunoprecipitation
Segment by Application
Drug Development
Biomedical Research
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Co-immunoprecipitation (Co-IP) Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Tag Protein Immunoprecipitation
1.2.3 Non Tagged Protein Immunoprecipitation
1.2.4 Chromatin Immunoprecipitation
1.3 麻豆原创 by Application
1.3.1 Global Co-immunoprecipitation (Co-IP) Service 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Drug Development
1.3.3 Biomedical Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Co-immunoprecipitation (Co-IP) Service 麻豆原创 Perspective (2020-2031)
2.2 Global Co-immunoprecipitation (Co-IP) Service Growth Trends by Region
2.2.1 Global Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Co-immunoprecipitation (Co-IP) Service Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Co-immunoprecipitation (Co-IP) Service Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Co-immunoprecipitation (Co-IP) Service 麻豆原创 Dynamics
2.3.1 Co-immunoprecipitation (Co-IP) Service Industry Trends
2.3.2 Co-immunoprecipitation (Co-IP) Service 麻豆原创 Drivers
2.3.3 Co-immunoprecipitation (Co-IP) Service 麻豆原创 Challenges
2.3.4 Co-immunoprecipitation (Co-IP) Service 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Co-immunoprecipitation (Co-IP) Service Players by Revenue
3.1.1 Global Top Co-immunoprecipitation (Co-IP) Service Players by Revenue (2020-2025)
3.1.2 Global Co-immunoprecipitation (Co-IP) Service Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Top Co-immunoprecipitation (Co-IP) Service Players by Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Co-immunoprecipitation (Co-IP) Service Revenue
3.4 Global Co-immunoprecipitation (Co-IP) Service 麻豆原创 Concentration Ratio
3.4.1 Global Co-immunoprecipitation (Co-IP) Service 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Co-immunoprecipitation (Co-IP) Service Revenue in 2024
3.5 Global Key Players of Co-immunoprecipitation (Co-IP) Service Head office and Area Served
3.6 Global Key Players of Co-immunoprecipitation (Co-IP) Service, Product and Application
3.7 Global Key Players of Co-immunoprecipitation (Co-IP) Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Co-immunoprecipitation (Co-IP) Service Breakdown Data by Type
4.1 Global Co-immunoprecipitation (Co-IP) Service Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Co-immunoprecipitation (Co-IP) Service Forecasted 麻豆原创 Size by Type (2026-2031)
5 Co-immunoprecipitation (Co-IP) Service Breakdown Data by Application
5.1 Global Co-immunoprecipitation (Co-IP) Service Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Co-immunoprecipitation (Co-IP) Service Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size (2020-2031)
6.2 North America Co-immunoprecipitation (Co-IP) Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Country (2020-2025)
6.4 North America Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size (2020-2031)
7.2 Europe Co-immunoprecipitation (Co-IP) Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Country (2020-2025)
7.4 Europe Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Co-immunoprecipitation (Co-IP) Service 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size (2020-2031)
9.2 Latin America Co-immunoprecipitation (Co-IP) Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Co-immunoprecipitation (Co-IP) Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Co-immunoprecipitation (Co-IP) Service 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Creative Proteomics
11.1.1 Creative Proteomics Company Details
11.1.2 Creative Proteomics Business Overview
11.1.3 Creative Proteomics Co-immunoprecipitation (Co-IP) Service Introduction
11.1.4 Creative Proteomics Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.1.5 Creative Proteomics Recent Development
11.2 Lifeasible
11.2.1 Lifeasible Company Details
11.2.2 Lifeasible Business Overview
11.2.3 Lifeasible Co-immunoprecipitation (Co-IP) Service Introduction
11.2.4 Lifeasible Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.2.5 Lifeasible Recent Development
11.3 ThermoFisher Scientific
11.3.1 ThermoFisher Scientific Company Details
11.3.2 ThermoFisher Scientific Business Overview
11.3.3 ThermoFisher Scientific Co-immunoprecipitation (Co-IP) Service Introduction
11.3.4 ThermoFisher Scientific Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.3.5 ThermoFisher Scientific Recent Development
11.4 Profacgen
11.4.1 Profacgen Company Details
11.4.2 Profacgen Business Overview
11.4.3 Profacgen Co-immunoprecipitation (Co-IP) Service Introduction
11.4.4 Profacgen Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.4.5 Profacgen Recent Development
11.5 Creative BioMart
11.5.1 Creative BioMart Company Details
11.5.2 Creative BioMart Business Overview
11.5.3 Creative BioMart Co-immunoprecipitation (Co-IP) Service Introduction
11.5.4 Creative BioMart Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.5.5 Creative BioMart Recent Development
11.6 Biologics International Corp
11.6.1 Biologics International Corp Company Details
11.6.2 Biologics International Corp Business Overview
11.6.3 Biologics International Corp Co-immunoprecipitation (Co-IP) Service Introduction
11.6.4 Biologics International Corp Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.6.5 Biologics International Corp Recent Development
11.7 Creative Diagnostics
11.7.1 Creative Diagnostics Company Details
11.7.2 Creative Diagnostics Business Overview
11.7.3 Creative Diagnostics Co-immunoprecipitation (Co-IP) Service Introduction
11.7.4 Creative Diagnostics Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.7.5 Creative Diagnostics Recent Development
11.8 CD BioSciences
11.8.1 CD BioSciences Company Details
11.8.2 CD BioSciences Business Overview
11.8.3 CD BioSciences Co-immunoprecipitation (Co-IP) Service Introduction
11.8.4 CD BioSciences Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.8.5 CD BioSciences Recent Development
11.9 Beijing Abace Biology
11.9.1 Beijing Abace Biology Company Details
11.9.2 Beijing Abace Biology Business Overview
11.9.3 Beijing Abace Biology Co-immunoprecipitation (Co-IP) Service Introduction
11.9.4 Beijing Abace Biology Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.9.5 Beijing Abace Biology Recent Development
11.10 Nanjing Detai Bioengineering
11.10.1 Nanjing Detai Bioengineering Company Details
11.10.2 Nanjing Detai Bioengineering Business Overview
11.10.3 Nanjing Detai Bioengineering Co-immunoprecipitation (Co-IP) Service Introduction
11.10.4 Nanjing Detai Bioengineering Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.10.5 Nanjing Detai Bioengineering Recent Development
11.11 Guangzhou Fitgene Biotechnology
11.11.1 Guangzhou Fitgene Biotechnology Company Details
11.11.2 Guangzhou Fitgene Biotechnology Business Overview
11.11.3 Guangzhou Fitgene Biotechnology Co-immunoprecipitation (Co-IP) Service Introduction
11.11.4 Guangzhou Fitgene Biotechnology Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.11.5 Guangzhou Fitgene Biotechnology Recent Development
11.12 Nanjing Zoonbio Biotechnology
11.12.1 Nanjing Zoonbio Biotechnology Company Details
11.12.2 Nanjing Zoonbio Biotechnology Business Overview
11.12.3 Nanjing Zoonbio Biotechnology Co-immunoprecipitation (Co-IP) Service Introduction
11.12.4 Nanjing Zoonbio Biotechnology Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.12.5 Nanjing Zoonbio Biotechnology Recent Development
11.13 Shanghai Beyotime Biotechnology
11.13.1 Shanghai Beyotime Biotechnology Company Details
11.13.2 Shanghai Beyotime Biotechnology Business Overview
11.13.3 Shanghai Beyotime Biotechnology Co-immunoprecipitation (Co-IP) Service Introduction
11.13.4 Shanghai Beyotime Biotechnology Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.13.5 Shanghai Beyotime Biotechnology Recent Development
11.14 Beijing Bio-Tech Pack Scientific
11.14.1 Beijing Bio-Tech Pack Scientific Company Details
11.14.2 Beijing Bio-Tech Pack Scientific Business Overview
11.14.3 Beijing Bio-Tech Pack Scientific Co-immunoprecipitation (Co-IP) Service Introduction
11.14.4 Beijing Bio-Tech Pack Scientific Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.14.5 Beijing Bio-Tech Pack Scientific Recent Development
11.15 Wuhan Genecreate
11.15.1 Wuhan Genecreate Company Details
11.15.2 Wuhan Genecreate Business Overview
11.15.3 Wuhan Genecreate Co-immunoprecipitation (Co-IP) Service Introduction
11.15.4 Wuhan Genecreate Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.15.5 Wuhan Genecreate Recent Development
11.16 Wuhan Biorun BioSciences
11.16.1 Wuhan Biorun BioSciences Company Details
11.16.2 Wuhan Biorun BioSciences Business Overview
11.16.3 Wuhan Biorun BioSciences Co-immunoprecipitation (Co-IP) Service Introduction
11.16.4 Wuhan Biorun BioSciences Revenue in Co-immunoprecipitation (Co-IP) Service Business (2020-2025)
11.16.5 Wuhan Biorun BioSciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Creative Proteomics
Lifeasible
ThermoFisher Scientific
Profacgen
Creative BioMart
Biologics International Corp
Creative Diagnostics
CD BioSciences
Beijing Abace Biology
Nanjing Detai Bioengineering
Guangzhou Fitgene Biotechnology
Nanjing Zoonbio Biotechnology
Shanghai Beyotime Biotechnology
Beijing Bio-Tech Pack Scientific
Wuhan Genecreate
Wuhan Biorun BioSciences
听
听
*If Applicable.
